FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.
Published
Journal Article
Full Text
Duke Authors
Cited Authors
- Klintmalm, GB; Kaplan, B; Kirk, AD
Published Date
- April 2019
Published In
Volume / Issue
- 19 / 4
Start / End Page
- 971 - 972
PubMed ID
- 30552744
Pubmed Central ID
- 30552744
Electronic International Standard Serial Number (EISSN)
- 1600-6143
Digital Object Identifier (DOI)
- 10.1111/ajt.15215
Language
- eng
Conference Location
- United States